Atb Cap Markets Issues Negative Estimate for Tilray Earnings

Tilray Inc (NASDAQ:TLRY) – Equities researchers at Atb Cap Markets cut their FY2028 earnings per share (EPS) estimates for shares of Tilray in a report issued on Monday, December 16th. Atb Cap Markets analyst F. Gomes now expects that the company will earn $0.01 per share for the year, down from their prior forecast of $0.06. The consensus estimate for Tilray’s current full-year earnings is ($0.14) per share.

Separately, Roth Mkm cut their target price on shares of Tilray from $2.00 to $1.75 and set a “neutral” rating for the company in a research report on Friday, October 11th.

Tilray Trading Up 3.3 %

Tilray stock opened at $1.24 on Wednesday. The company has a quick ratio of 1.57, a current ratio of 2.47 and a debt-to-equity ratio of 0.08. Tilray has a 12 month low of $1.15 and a 12 month high of $2.97. The company’s fifty day simple moving average is $1.47 and its 200-day simple moving average is $1.67. The stock has a market cap of $1.12 billion, a P/E ratio of -4.50 and a beta of 2.08.

Tilray (NASDAQ:TLRY) last posted its quarterly earnings data on Thursday, October 10th. The company reported ($0.04) EPS for the quarter, hitting analysts’ consensus estimates of ($0.04). Tilray had a negative return on equity of 2.00% and a negative net margin of 26.79%. The company had revenue of $200.00 million for the quarter, compared to the consensus estimate of $218.70 million. During the same quarter in the previous year, the business earned ($0.10) EPS. The company’s quarterly revenue was up 13.0% compared to the same quarter last year.

Insider Buying and Selling

In other Tilray news, CFO Carl A. Merton bought 26,000 shares of Tilray stock in a transaction dated Friday, November 15th. The stock was bought at an average price of $1.36 per share, with a total value of $35,360.00. Following the completion of the transaction, the chief financial officer now owns 26,000 shares in the company, valued at $35,360. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.87% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of TLRY. Ferguson Wellman Capital Management Inc. bought a new stake in shares of Tilray in the third quarter worth $26,000. Signature Estate & Investment Advisors LLC purchased a new stake in shares of Tilray in the second quarter worth approximately $29,000. Jeppson Wealth Management LLC bought a new position in Tilray during the 2nd quarter valued at $33,000. Vanguard Capital Wealth Advisors purchased a new position in Tilray during the second quarter worth about $34,000. Finally, Pallas Capital Advisors LLC bought a new position in shares of Tilray in the second quarter valued at approximately $37,000. Institutional investors own 9.35% of the company’s stock.

Tilray Company Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.